Ret Oncogene and Thyroid Carcinoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Genetic Syndromes & Gene Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.4172/2157-7412.1000214
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The involvement of the RET variant G691S in medullary thyroid carcinoma enlightened by a meta‐analysis study

  2013cited by this paper
• In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

  2013cited by this paper
• Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.

  2013cited by this paper
• Cabozantinib in progressive medullary thyroid cancer.

  2013cited by this paper
• Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.

  2013cited by this paper
• The clinical spectrum of RET proto-oncogene mutations in codon 790.

  2013cited by this paper
• Novel targets in non-small cell lung cancer: ROS1 and RET fusions.

  2013cited by this paper
• Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

  2013cited by this paper
• Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2

  2012cited by this paper
• RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation

  2012cited by this paper
• Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

  2012cited by this paper
• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

  2012cited by this paper
• 2012 European Thyroid Association Guidelines for Genetic Testing and Its Clinical Consequences in Medullary Thyroid Cancer

  2012cited by this paper
• Low Prevalence of the Somatic M918T RET Mutation in Micro-Medullary Thyroid Cancer

  2012cited by this paper
• Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.

  2012cited by this paper
• Modifications in the papillary thyroid cancer gene profile over the last 15 years.

  2012cited by this paper
• RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC)

  2011influential reference
• Anti-tumor activity of motesanib in a medullary thyroid cancer model

  2011cited by this paper
• In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

  2011cited by this paper
• Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application.

  2011cited by this paper
• High growth rate of benign thyroid nodules bearing RET/PTC rearrangements.

  2011cited by this paper
• Chromosomal Rearrangements in Post-Chernobyl Papillary Thyroid Carcinomas: Evaluation by Spectral Karyotyping and Automated Interphase FISH

  2011cited by this paper
• Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation

  2011cited by this paper
• Targeted therapies for thyroid tumors

  2011cited by this paper
• Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.

  2011cited by this paper
• Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.

  2010cited by this paper
• Role of H2O2 in RET/PTC1 chromosomal rearrangement produced by ionizing radiation in human thyroid cells.

  2010cited by this paper
• RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components

  2010cited by this paper
• Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.

  2010cited by this paper
• Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome.

  2010cited by this paper
• Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma.

  2010cited by this paper
• DNA Breaks at Fragile Sites Generate Oncogenic RET/PTC Rearrangements in Human Thyroid Cells

  2010cited by this paper
• Hydrogen peroxide induces DNA single- and double-strand breaks in thyroid cells and is therefore a potential mutagen for this organ.

  2009cited by this paper
• Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas

  2009cited by this paper
• Molecular pathology of differentiated thyroid cancer.

  2009cited by this paper
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

  2009cited by this paper
• Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

  2009cited by this paper
• Fine-needle aspiration of the thyroid: today and tomorrow.

  2008cited by this paper
• BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

  2008cited by this paper
• Management of the solitary thyroid nodule.

  2008cited by this paper
• Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791 *

  2008cited by this paper
• Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

  2008cited by this paper
• RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.

  2007cited by this paper
• BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

  2007cited by this paper
• RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

  2007influential reference
• European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

  2006cited by this paper
• Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.

  2006cited by this paper
• RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

  2006cited by this paper
• Cancer consequences of the Chernobyl accident: 20 years on

  2006cited by this paper
• RET rearrangements in post-Chernobyl papillary thyroid carcinomas with a short latency analysed by interphase FISH

  2006cited by this paper
• BAY 43-9006 inhibition of oncogenic RET mutants.

  2006cited by this paper
• Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

  2006cited by this paper
• RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.

  2006cited by this paper
• RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

  2006cited by this paper
• Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

  2006cited by this paper
• ret/PTC1 and ret/PTC3 in thyroid tumors from Chernobyl liquidators: comparison with sporadic tumors from Ukrainian and French patients.

  2005cited by this paper
• RET tyrosine kinase signaling in development and cancer.

  2005cited by this paper
• ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma

  2005cited by this paper
• Risk of thyroid cancer after exposure to 131I in childhood.

  2005cited by this paper
• Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation.

  2005cited by this paper
• Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

  2005cited by this paper
• Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma

  2004cited by this paper
• A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure.

  2004cited by this paper
• Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature.

  2004cited by this paper
• Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.

  2004cited by this paper
• Early malignant progression of hereditary medullary thyroid cancer.

  2003cited by this paper
• Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.

  2003cited by this paper
• The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

  2002cited by this paper
• The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.

  2002cited by this paper
• Conservation of RET proto-oncogene splicing variants and implications for RET isoform function

  2002cited by this paper
• Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas

  2001cited by this paper
• Treatment of medullary thyroid carcinoma: an update.

  2001cited by this paper
• RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.

  2001cited by this paper
• Prognostic value of codon 918 (ATG→ACG) RET proto‐oncogene mutations in sporadic medullary thyroid carcinoma

  2001cited by this paper
• Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.

  2001cited by this paper
• RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma.

  2001cited by this paper
• The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.

  2000cited by this paper
• ret/PTC-1 Activation in Hashimoto Thyroiditis

  2000cited by this paper
• RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH

  2000cited by this paper
• Prevalence and distribution of ret/ptc 1, 2, and 3 in papillary thyroid carcinoma in New Caledonia and Australia.

  2000cited by this paper
• Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma

  2000cited by this paper
• High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant.

  1999cited by this paper
• Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation

  1999cited by this paper
• Oncogene profile of papillary thyroid carcinoma.

  1999cited by this paper
• A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene.

  1999cited by this paper
• RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.

  1998cited by this paper
• Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters.

  1998cited by this paper
• The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.

  1998cited by this paper
• Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma.

  1998cited by this paper
• A rapid method for DNA extraction from fine-needle aspiration biopsies of thyroid tumors, and subsequent RET mutation analysis.

  1998cited by this paper
• Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

  1997cited by this paper
• Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation.

  1997cited by this paper
• Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children.

  1997cited by this paper
• Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene

  1997cited by this paper
• High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation

  1997cited by this paper
• Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.

  1996influential reference
• Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice.

  1996cited by this paper
• The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

  1996cited by this paper
• Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.

  1996cited by this paper
• Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident.

  1995cited by this paper

• Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study

  2023cites this paper
• Novel RET Proto-oncogene Variants Identified in Turkish Patients with Thyroid Carcinoma.

  2020cites this paper
• Somatic Mutations in Exons 10, 11, and 16 of the RET Protooncogene in Medullary Thyroid Carcinoma Patients

  2020cites this paper
• Investigating the expression and promoter methylation of RET gene in patients with medullary thyroid cancer with unmutated RET

  2019cites this paper
• Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing

  2019cites this paper
• Hereditary and familial thyroid tumours

  2018cites this paper
• The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A

  2017cites this paper
• A Case of Lacrimo-Auriculo-Dento-Digital Syndrome with Multiple Congenitally Missing Teeth

  2016cites this paper
• New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations

  2016cites this paper
• Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland

  2016cites this paper
• RESEARCH AND REVIEWS: JOURNAL OF ENGINEERING AND TECHNOLOGY Genetic syndromes and Involvement of Gene Therapy

  2015cites this paper